logo

Last Update

This profile was last updated on 8/29/2011 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Barry Freehill?

Barry Freehill

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Background Information

Employment History

Executive Advisory Board Member

Community Consortium


Web References(1 Total References)


Synopsis: April 2000

www.communityconsortium.org [cached]

Barry Freehill, also a community member, presented a concept sheet at the March SAC/CAB for a randomized, controlled trial to determine if continuing 3TC when switching to a new HAART regimen in patients with the M184V mutation is associated with a slower rate of development of resistance and virologic failure as compared to not continuing 3TC when switching to a new HAART regimen.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory